ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

New Research Projects Proposed For Immunology

September 30, 1977

SEC Notifies ImClone It May Bring Action Against Company

June 21, 2002

FDA’s Oncologic Drugs Advisory Committee recommended approval of three drugs for cancer, voted down one.

September 16, 2005

Degarelix Active In Phase II Trial In Prostate Cancer

October 29, 2004

Deflecting Earmarks, NCI Advisors Lay Out Research Opportunities In Breast, Prostate

February 26, 1999

Amazon Links To NCI Materials, A First For NIH Health Content.

July 14, 2000